Organon & Co. (NYSE:OGN) Shares Unloaded Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Organon & Co. (NYSE:OGN). In a filing disclosed on August 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Organon & Co. stock on August 5th. The trade occurred in the Representative’s “HERN FAMILY FOUNDATION” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Diageo (NYSE:DEO) on 8/5/2026.
• Sold $1,001 – $15,000 in shares of Estee Lauder Companies (NYSE:EL) on 8/5/2026.
• Sold $1,001 – $15,000 in shares of Mondelez International (NASDAQ:MDLZ) on 8/5/2026.
• Sold $1,001 – $15,000 in shares of Versant (NASDAQ:VSNT) on 8/5/2026.
• Sold $1,001 – $15,000 in shares of Comcast (NASDAQ:CMCSA) on 8/5/2026.
• Sold $1,001 – $15,000 in shares of Kenvue (NYSE:KVUE) on 8/5/2026.

Organon & Co. Price Performance

Organon & Co. stock opened at $13.65 on Wednesday. Organon & Co. has a 52 week low of $5.69 and a 52 week high of $13.66. The company’s 50 day moving average price is $13.50 and its two-hundred day moving average price is $10.65. The stock has a market cap of $3.59 billion, a P/E ratio of 17.73, a P/E/G ratio of 1.26 and a beta of 1.55. The company has a quick ratio of 1.44, a current ratio of 1.95 and a debt-to-equity ratio of 8.43.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $0.02 dividend. The ex-dividend date is Friday, August 14th. This represents a $0.08 annualized dividend and a yield of 0.6%. Organon & Co.’s dividend payout ratio (DPR) is 10.39%.

Hedge Funds Weigh In On Organon & Co.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC grew its position in shares of Organon & Co. by 105.2% during the fourth quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock worth $61,282,000 after purchasing an additional 4,394,814 shares in the last quarter. UBS Group AG raised its stake in Organon & Co. by 55.2% during the fourth quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after purchasing an additional 1,527,492 shares in the last quarter. First Trust Advisors LP increased its stake in Organon & Co. by 78.1% during the first quarter. First Trust Advisors LP now owns 3,227,320 shares of the company’s stock worth $19,332,000 after acquiring an additional 1,415,239 shares during the last quarter. Private Management Group Inc. raised its holdings in Organon & Co. by 38.3% during the 4th quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock valued at $31,169,000 after buying an additional 1,204,979 shares during the period. Finally, Balyasny Asset Management L.P. boosted its stake in shares of Organon & Co. by 102.1% during the 3rd quarter. Balyasny Asset Management L.P. now owns 2,240,149 shares of the company’s stock worth $23,925,000 after purchasing an additional 1,131,941 shares during the period. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

OGN has been the topic of several research analyst reports. Piper Sandler raised Organon & Co. from an “underweight” rating to a “neutral” rating and boosted their price objective for the stock from $5.00 to $14.00 in a research report on Tuesday, April 28th. BNP Paribas Exane restated a “neutral” rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Weiss Ratings lowered shares of Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 3rd. Finally, Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 14th. Five equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Organon & Co. presently has a consensus rating of “Reduce” and an average target price of $11.40.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.